Literature DB >> 28436978

Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation.

L Decook1, Y-H Chang2, J Slack1, D Gastineau1, J Leis1, P Noel1, J Palmer1, L Sproat1, M Sorror3, N Khera1.   

Abstract

Comorbidities affect clinical outcomes and costs in medicine. The hematopoietic cell transplantation (HCT)-specific comorbidity index (HCT-CI) predicts mortality risk after HCT. Its association with resource utilization (RU) is unknown. In this single-center, retrospective study, we examined the association of HCT-CI with RU (readmissions, length of hospital stay (LOS) and days out of hospital alive (DOHA)) in first 100 days (n=328) and 1 year (n=226) in allogeneic HCT patients from January 2010 to June 2014. Age, disease risk, conditioning and use of antithymocyte globulin were significantly different in the four groups with HCT-CI 0 to1 (n=138), 2 (n=56), 3 (n=55) or ⩾4 (n=79). Although the readmissions were higher in the first 100 days for patients with HCT-CI >0-1 (P=0.03), they were not significantly different in patients over 1 year (P=0.13). In the multivariable analysis, patients with HCT-CI score of >0 to 1 had increased LOS and fewer DOHA in both 100 days and 1 year after HCT. In this exploratory analysis, we found that HCT-CI >0 to 1 is associated with increased RU after allogeneic HCT. Recognizing predictors of RU can identify patients at risk of high utilization and help understand what drives health-care costs.

Entities:  

Mesh:

Year:  2017        PMID: 28436978     DOI: 10.1038/bmt.2017.70

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  33 in total

1.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

2.  Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

Authors:  Mohamed L Sorror; Paul J Martin; Rainer F Storb; Smita Bhatia; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Christopher Davis; H Joachim Deeg; Stephanie J Lee; David G Maloney; Brenda M Sandmaier; Frederick R Appelbaum; Theodore A Gooley
Journal:  Blood       Date:  2014-05-05       Impact factor: 22.113

3.  Comorbidity and social factors predicted hospitalization in frail elderly patients.

Authors:  Francesco Landi; Graziano Onder; Matteo Cesari; Christian Barillaro; Fabrizia Lattanzio; Pier Ugo Carbonin; Roberto Bernabei
Journal:  J Clin Epidemiol       Date:  2004-08       Impact factor: 6.437

4.  Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival.

Authors:  Laura Spring; Shuli Li; Robert J Soiffer; Joseph H Antin; Edwin P Alyea; Brett Glotzbecker
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-05       Impact factor: 5.742

5.  Costs of pediatric allogeneic hematopoietic-cell transplantation.

Authors:  Navneet S Majhail; Jaya M Mothukuri; Margaret L Macmillan; Michael R Verneris; Paul J Orchard; John E Wagner; Daniel J Weisdorf
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

6.  Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs.

Authors:  Stephanie J Lee; David Zahrieh; Edwin P Alyea; Edie Weller; Vincent T Ho; Joseph H Antin; Robert J Soiffer
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

7.  Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.

Authors:  Navneet S Majhail; Jaya M Mothukuri; Claudio G Brunstein; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2009-03-09       Impact factor: 5.742

8.  Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.

Authors:  Mohamed Sorror; Barry Storer; Brenda M Sandmaier; David G Maloney; Thomas R Chauncey; Amelia Langston; Richard T Maziarz; Michael Pulsipher; Peter A McSweeney; Rainer Storb
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

9.  Comorbidity and the use of primary care and specialist care in the elderly.

Authors:  Barbara Starfield; Klaus W Lemke; Robert Herbert; Wendy D Pavlovich; Gerard Anderson
Journal:  Ann Fam Med       Date:  2005 May-Jun       Impact factor: 5.707

10.  Impact of Nurse-Led, Multidisciplinary Home-Based Intervention on Event-Free Survival Across the Spectrum of Chronic Heart Disease: Composite Analysis of Health Outcomes in 1226 Patients From 3 Randomized Trials.

Authors:  Simon Stewart; Joshua F Wiley; Jocasta Ball; Yih-Kai Chan; Yasmin Ahamed; David R Thompson; Melinda J Carrington
Journal:  Circulation       Date:  2016-04-15       Impact factor: 29.690

View more
  1 in total

1.  Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population.

Authors:  Dylan Barth; Michael Singleton; Gregory Monohan; Brian McClune; Val Adams
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.